Text

PRECISION MSK MEDICINE — REDUCED COSTS

GET OVER 3:1 ROI ON MUSCULOSKELETAL CARE AND REDUCE THE NEED FOR ELECTIVE TOTAL KNEE SURGERY BY UP TO 89%1

FOR
EMPLOYERS

FOR
CONSULTANTS

FOR
HEALTH PLANS

ORGANIZATIONS TRUST APOS® – LOWER COSTS, GET RESULTS

WHAT IS APOS®?

Apos® is a targeted innovative approach to addressing knee osteoarthritis, and chronic hip and lower back pain. By considering each patient’s unique anatomy, biomechanics, neuromuscular responses, and medical history, Apos® delivers personalized treatment tailored to individual needs.

Contact Us

WHY CHOOSE APOS®?

Independent reviews of real-world claims data across Medicaid, Medicare Advantage, and Commercial populations reveal an ROI of over 3:1 within the first year of implementation1.

In one study, Apos® saved an average of $3,689 per patient1, substantially reducing healthcare expenses for a commercial payor.

WHAT OUR PATIENTS SAY

“THE FIRST DAY I TRIED THEM, I CRIED—BECAUSE I COULD WALK NORMALLY AGAIN.”

​- ROBERT L.​
FORMER MARATHON RUNNER WITH CHRONIC KNEE PAIN​

“NOW I CAN JOG AS FAST AS I WOULD NORMALLY JOG.”

​- GEORGE T.
​FDNY EMPLOYEE WHO HAD CHRONIC BACK PAIN​

“THANKS TO APOS® I’M ABLE TO RIDE HORSES, SKI, AND DANCE AGAIN.”​

– JONQUILLE S.​
BROKE FEMUR BONE IN HORSE-RIDING ACCIDENT​

BACKED BY CLINICAL RESEARCH

JAMA: THE BIOTOK RANDOMIZED CLINICAL TRIAL, EFFECT OF APOS® ON KNEE PAIN IN PEOPLE WITH KNEE OSTEOARTHRITIS

Leading experts in osteoarthritis, including David Felson, MD, MPH, Stephan Reichenbach, MD, MSc, and Peter Jüni, MD, conducted an independent double-blind RCT study

REDUCTION IN PAIN AND IMPROVEMENT IN FUNCTION EXCEEDS THE THRESHOLD FOR CLINICAL SIGNIFICANCE FOR CLINICAL SIGNIFICANCE

92
%

REPORTED
>30% REDUCTION IN PAIN

87
%

REPORTED
>50% REDUCTION IN PAIN

70
%

AVG.
REDUCTION IN PAIN

60
%

AVG.
IMPROVEMENT IN FUNCTION

As a reference, a different randomized controlled trial (RCT) comparing total knee replacement with non-invasive intervention vs. non-invasive intervention only demonstrated a number needed to treat (NNT) of 7.4 to achieve a 15% reduction in pain.

*Skou S.T. et al. Osteoarthritis and Cartilage, 2018, 26, 1170-1180.

READ THE FULL STUDY

FAQs

Apos® reduces the need for expensive surgeries, injections, and treatments while improving employee health and improving ROIs. A recent study showed 43% reduction in MSK management costs within one year of implementation.1

Unlike traditional approaches, Apos® has a unique mechanism of action to treat the symptoms and the underlying causes of the pain in the comfort of the patient’s home with a carry-over effect by transforming the way one walks, resulting in unparalleled clinical and economic efficacy with safety, convenience, and satisfaction.

Our approach is backed by over 70 peer-reviewed clinical publications, including a recent study showing that 89% of eligible total knee replacement patients avoided surgery for up to 6 years with Apos®.4

Apos® is FDA cleared for treating knee osteoarthritis and FDA registered and evidence backed for chronic hip pain and non-specific lower back pain, offering personalized treatment for each patient’s needs.

Many feel relief right away as the device helps realign their joints. For others, it may take 3-6 months. Long-term relief happens because, over time, the muscles learn to stabilize the joints better, even when they are not wearing the device.2

Yes, studies show that Apos® can reduce the need for total knee replacement surgery by up to 89%.

Contact Us

CONTACT US TO IMPROVE YOUR MSK RESULTS WHILE REDUCING COSTS

SOURCES

  1. Reichenbach A, Felson DT, Hincapi CA, Heldner S, Butikofer L, Lenz A, da Costa BR, Bonel HM, Jones RK, Hawker GA, Juni P. Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis. The BIOTOK Randomized Clinical Trial. JAMA 2020; 323(18):1802-1812.
  2. Veeramachaneni R et al. Clinical outcomes of a new non-invasive biomechanical intervention for patients with chronic low back pain. A Randomized Clinical Trial. Aug;10(8):836-842. doi: 10.1016/j.pmrj.2018.02.005. Epub 2018 Feb 21.
  3. Josh Mark, Shirley Shema-Shiratzky, Joel Sommer, Tim Nolan, Ganit Segal. Reduction in Healthcare Resource Utilization Following Treatment With a Home-Based Footworn Device in Patients With Knee Osteoarthritis: A Retrospective Claims Analysis. J Health Econ Outcomes Res. 2024 May 16; 11(1):134-140. doi: 10.36469/001c.117155.eCollection 2024. Link to article
  4. Benn, R., Rawson, L., & Phillips, A. (2023). Utilising a non-surgical intervention in the knee osteoarthritis care pathway: A 6-year retrospective audit on NHS patients. Therapeutic Advances in Musculoskeletal Disease. Link to article